Clinical Trial Update: A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and pharmacokinetics of ataluren in young children with nonsense mutation Duchenne muscular dystrophy has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ataluren (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Nonsene Mutation Duchenne Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2024-04-01